Harrow Health, Inc. (HROW) Stock

Harrow Health, Inc. (HROW) is a Healthcare stock trading at $42.93 (as of 2026-06-18), with a market capitalization of $1.31B and a trailing P/E of -92.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Harrow Health, Inc. is an ophthalmic-focused healthcare company that develops and commercializes treatments in eye care through businesses that include ImprimisRx and DEXYCU. It also holds equity interests in Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals, and owns royalty rights in certain clinical-stage drug candidates.

Valuation — source: SEC EDGAR (first-party)
Price	$42.93
Market Cap	$1.31B
P/E Ratio	-92.7
EV / EBITDA	70.4
Price / Book	46.29
Price / Sales	4.88
DCF Value (model)	$24.37
DCF Upside vs Price	-43.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$272.30M
Net Margin	-1.9%
Return on Equity	-52.8%
Debt / Equity	10.58
Current Ratio	2.48
Revenue Growth (YoY)	-7.6%
EPS Growth (YoY)	48.0%
FCF Growth (YoY)	-147.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	3.49 (safe)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-92.7
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-542.1%
vs Industry	-636.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Opaleye Management Inc. ($99.86M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Mark L. Baum
Employees	382
Country	US
IPO Date	2007-09-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.